Table 1 Baseline characteristics from Phase 1
Variable | n = 678 |
|---|---|
Age, years | 63 ± 8 |
Non-Hispanic white race | 525 (77%) |
Male sex | 375 (55%) |
Enrollment at Denver clinical site | 132 (19%) |
BMI, kg/m2 | 28.2 ± 5.8 |
Baseline heart rate, beats/min | 76 ± 12 |
Baseline oxygen saturation, % | 95.5 ± 2.4 |
Current Smokers | 248 (37%) |
Pack Year History | 52 ± 26 |
Coronary Artery Disease | 102 (15%) |
Congestive Heart Failure | 20 (3%) |
Hypertension | 315 (47%) |
Hyperlipidemia | 277 (41%) |
Asthma | 178 (26%) |
Sleep apnea | 137 (20%) |
Thromboembolic disease | 26 (4%) |
Peripheral vascular disease | 23 (3%) |
Cerebrovascular disease | 36 (5%) |
Gastroesophageal reflux disease | 215 (32%) |
FEV1, percent predicted | 54 ± 16 |
FEV1/FVC | 0.51 ± 0.12 |
GOLD 2 | 405 (59.7%) |
GOLD 3 | 215 (31.7%) |
GOLD 4 | 58 (8.6%) |
Percent emphysema, -950 HU | 12.7 ± 11.7 |
Percent gas trapping | 38 ± 19 |
PA/A ratio | 0.89 ± 0.13 |
PA/A ratio >1 | 127 (19%) |
Severe AECOPD 1-year prior | 101 (15%) |
MMRC | 1.8 ± 1.4 |
SGRQ, total | 35 ± 21 |
6MWD, ft | 1277 ± 361 |